nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—Vaginal inflammation—Doxorubicin—pancreatic cancer	0.00236	0.00236	CcSEcCtD
Ceftazidime—Pain—Erlotinib—pancreatic cancer	0.00234	0.00234	CcSEcCtD
Ceftazidime—Bronchospasm—Docetaxel—pancreatic cancer	0.00233	0.00233	CcSEcCtD
Ceftazidime—Coma—Epirubicin—pancreatic cancer	0.00233	0.00233	CcSEcCtD
Ceftazidime—Nervous system disorder—Sunitinib—pancreatic cancer	0.00232	0.00232	CcSEcCtD
Ceftazidime—Thrombocytopenia—Sunitinib—pancreatic cancer	0.00232	0.00232	CcSEcCtD
Ceftazidime—Skin disorder—Sunitinib—pancreatic cancer	0.0023	0.0023	CcSEcCtD
Ceftazidime—Colitis—Doxorubicin—pancreatic cancer	0.00227	0.00227	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00226	0.00226	CcSEcCtD
Ceftazidime—Skin exfoliation—Doxorubicin—pancreatic cancer	0.00225	0.00225	CcSEcCtD
Ceftazidime—Candida infection—Doxorubicin—pancreatic cancer	0.00225	0.00225	CcSEcCtD
Ceftazidime—Pancytopenia—Docetaxel—pancreatic cancer	0.00225	0.00225	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00224	0.00224	CcSEcCtD
Ceftazidime—Vaginal infection—Doxorubicin—pancreatic cancer	0.00223	0.00223	CcSEcCtD
Ceftazidime—Neutropenia—Docetaxel—pancreatic cancer	0.00222	0.00222	CcSEcCtD
Ceftazidime—Aplastic anaemia—Doxorubicin—pancreatic cancer	0.00222	0.00222	CcSEcCtD
Ceftazidime—Urticaria—Tamoxifen—pancreatic cancer	0.0022	0.0022	CcSEcCtD
Ceftazidime—Abdominal pain—Tamoxifen—pancreatic cancer	0.00219	0.00219	CcSEcCtD
Ceftazidime—Abdominal pain—Erlotinib—pancreatic cancer	0.00216	0.00216	CcSEcCtD
Ceftazidime—Body temperature increased—Erlotinib—pancreatic cancer	0.00216	0.00216	CcSEcCtD
Ceftazidime—Vision blurred—Fluorouracil—pancreatic cancer	0.00216	0.00216	CcSEcCtD
Ceftazidime—Coma—Doxorubicin—pancreatic cancer	0.00216	0.00216	CcSEcCtD
Ceftazidime—Phlebitis—Epirubicin—pancreatic cancer	0.00215	0.00215	CcSEcCtD
Ceftazidime—Leukopenia—Irinotecan—pancreatic cancer	0.00214	0.00214	CcSEcCtD
Ceftazidime—Thrombophlebitis—Epirubicin—pancreatic cancer	0.00214	0.00214	CcSEcCtD
Ceftazidime—Paraesthesia—Sunitinib—pancreatic cancer	0.00213	0.00213	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Epirubicin—pancreatic cancer	0.00212	0.00212	CcSEcCtD
Ceftazidime—Infestation—Docetaxel—pancreatic cancer	0.00212	0.00212	CcSEcCtD
Ceftazidime—Infestation NOS—Docetaxel—pancreatic cancer	0.00212	0.00212	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Docetaxel—pancreatic cancer	0.0021	0.0021	CcSEcCtD
Ceftazidime—Leukopenia—Gemcitabine—pancreatic cancer	0.00209	0.00209	CcSEcCtD
Ceftazidime—Renal failure—Docetaxel—pancreatic cancer	0.00208	0.00208	CcSEcCtD
Ceftazidime—Jaundice—Docetaxel—pancreatic cancer	0.00206	0.00206	CcSEcCtD
Ceftazidime—Leukopenia—Fluorouracil—pancreatic cancer	0.00205	0.00205	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00205	0.00205	CcSEcCtD
Ceftazidime—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00204	0.00204	CcSEcCtD
Ceftazidime—Pain—Sunitinib—pancreatic cancer	0.00203	0.00203	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.002	0.002	CcSEcCtD
Ceftazidime—Phlebitis—Doxorubicin—pancreatic cancer	0.00199	0.00199	CcSEcCtD
Ceftazidime—Convulsion—Fluorouracil—pancreatic cancer	0.00198	0.00198	CcSEcCtD
Ceftazidime—Hot flush—Epirubicin—pancreatic cancer	0.00198	0.00198	CcSEcCtD
Ceftazidime—Thrombophlebitis—Doxorubicin—pancreatic cancer	0.00198	0.00198	CcSEcCtD
Ceftazidime—Agranulocytosis—Docetaxel—pancreatic cancer	0.00197	0.00197	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00197	0.00197	CcSEcCtD
Ceftazidime—Menopausal symptoms—Epirubicin—pancreatic cancer	0.00196	0.00196	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Doxorubicin—pancreatic cancer	0.00196	0.00196	CcSEcCtD
Ceftazidime—Pruritus—Tamoxifen—pancreatic cancer	0.00196	0.00196	CcSEcCtD
Ceftazidime—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00195	0.00195	CcSEcCtD
Ceftazidime—Renal impairment—Epirubicin—pancreatic cancer	0.00195	0.00195	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00194	0.00194	CcSEcCtD
Ceftazidime—Pruritus—Erlotinib—pancreatic cancer	0.00194	0.00194	CcSEcCtD
Ceftazidime—Nervous system disorder—Irinotecan—pancreatic cancer	0.00191	0.00191	CcSEcCtD
Ceftazidime—Thrombocytopenia—Irinotecan—pancreatic cancer	0.00191	0.00191	CcSEcCtD
Ceftazidime—Haemoglobin—Docetaxel—pancreatic cancer	0.00191	0.00191	CcSEcCtD
Ceftazidime—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.0019	0.0019	CcSEcCtD
Ceftazidime—Haemorrhage—Docetaxel—pancreatic cancer	0.0019	0.0019	CcSEcCtD
Ceftazidime—Diarrhoea—Tamoxifen—pancreatic cancer	0.00189	0.00189	CcSEcCtD
Ceftazidime—Lethargy—Epirubicin—pancreatic cancer	0.00189	0.00189	CcSEcCtD
Ceftazidime—Abdominal pain—Sunitinib—pancreatic cancer	0.00187	0.00187	CcSEcCtD
Ceftazidime—Body temperature increased—Sunitinib—pancreatic cancer	0.00187	0.00187	CcSEcCtD
Ceftazidime—Diarrhoea—Erlotinib—pancreatic cancer	0.00187	0.00187	CcSEcCtD
Ceftazidime—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00187	0.00187	CcSEcCtD
Ceftazidime—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00186	0.00186	CcSEcCtD
Ceftazidime—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.00186	0.00186	CcSEcCtD
Ceftazidime—Skin disorder—Gemcitabine—pancreatic cancer	0.00185	0.00185	CcSEcCtD
Ceftazidime—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00183	0.00183	CcSEcCtD
Ceftazidime—Hot flush—Doxorubicin—pancreatic cancer	0.00183	0.00183	CcSEcCtD
Ceftazidime—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.00183	0.00183	CcSEcCtD
Ceftazidime—Dizziness—Tamoxifen—pancreatic cancer	0.00183	0.00183	CcSEcCtD
Ceftazidime—Hypotension—Irinotecan—pancreatic cancer	0.00182	0.00182	CcSEcCtD
Ceftazidime—Menopausal symptoms—Doxorubicin—pancreatic cancer	0.00182	0.00182	CcSEcCtD
Ceftazidime—Dizziness—Erlotinib—pancreatic cancer	0.00181	0.00181	CcSEcCtD
Ceftazidime—Renal impairment—Doxorubicin—pancreatic cancer	0.0018	0.0018	CcSEcCtD
Ceftazidime—Erythema multiforme—Docetaxel—pancreatic cancer	0.0018	0.0018	CcSEcCtD
Ceftazidime—Hypotension—Gemcitabine—pancreatic cancer	0.00178	0.00178	CcSEcCtD
Ceftazidime—Flushing—Docetaxel—pancreatic cancer	0.00176	0.00176	CcSEcCtD
Ceftazidime—Vomiting—Tamoxifen—pancreatic cancer	0.00176	0.00176	CcSEcCtD
Ceftazidime—Paraesthesia—Irinotecan—pancreatic cancer	0.00175	0.00175	CcSEcCtD
Ceftazidime—Lethargy—Doxorubicin—pancreatic cancer	0.00175	0.00175	CcSEcCtD
Ceftazidime—Hypotension—Fluorouracil—pancreatic cancer	0.00175	0.00175	CcSEcCtD
Ceftazidime—Hypersensitivity—Sunitinib—pancreatic cancer	0.00175	0.00175	CcSEcCtD
Ceftazidime—Rash—Tamoxifen—pancreatic cancer	0.00174	0.00174	CcSEcCtD
Ceftazidime—Dermatitis—Tamoxifen—pancreatic cancer	0.00174	0.00174	CcSEcCtD
Ceftazidime—Vomiting—Erlotinib—pancreatic cancer	0.00174	0.00174	CcSEcCtD
Ceftazidime—Headache—Tamoxifen—pancreatic cancer	0.00173	0.00173	CcSEcCtD
Ceftazidime—Rash—Erlotinib—pancreatic cancer	0.00173	0.00173	CcSEcCtD
Ceftazidime—Dermatitis—Erlotinib—pancreatic cancer	0.00172	0.00172	CcSEcCtD
Ceftazidime—Angiopathy—Docetaxel—pancreatic cancer	0.00172	0.00172	CcSEcCtD
Ceftazidime—Immune system disorder—Docetaxel—pancreatic cancer	0.00172	0.00172	CcSEcCtD
Ceftazidime—Headache—Erlotinib—pancreatic cancer	0.00171	0.00171	CcSEcCtD
Ceftazidime—Paraesthesia—Gemcitabine—pancreatic cancer	0.00171	0.00171	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00169	0.00169	CcSEcCtD
Ceftazidime—Paraesthesia—Fluorouracil—pancreatic cancer	0.00168	0.00168	CcSEcCtD
Ceftazidime—Pruritus—Sunitinib—pancreatic cancer	0.00168	0.00168	CcSEcCtD
Ceftazidime—Pain—Irinotecan—pancreatic cancer	0.00167	0.00167	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.00167	0.00167	CcSEcCtD
Ceftazidime—Nausea—Tamoxifen—pancreatic cancer	0.00164	0.00164	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00164	0.00164	CcSEcCtD
Ceftazidime—Pain—Gemcitabine—pancreatic cancer	0.00163	0.00163	CcSEcCtD
Ceftazidime—Nausea—Erlotinib—pancreatic cancer	0.00163	0.00163	CcSEcCtD
Ceftazidime—Diarrhoea—Sunitinib—pancreatic cancer	0.00162	0.00162	CcSEcCtD
Ceftazidime—Dysgeusia—Docetaxel—pancreatic cancer	0.00162	0.00162	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00161	0.00161	CcSEcCtD
Ceftazidime—Pain—Fluorouracil—pancreatic cancer	0.0016	0.0016	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.0016	0.0016	CcSEcCtD
Ceftazidime—Eosinophilia—Epirubicin—pancreatic cancer	0.00158	0.00158	CcSEcCtD
Ceftazidime—Dizziness—Sunitinib—pancreatic cancer	0.00157	0.00157	CcSEcCtD
Ceftazidime—Abdominal pain—Irinotecan—pancreatic cancer	0.00154	0.00154	CcSEcCtD
Ceftazidime—Body temperature increased—Irinotecan—pancreatic cancer	0.00154	0.00154	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.00154	0.00154	CcSEcCtD
Ceftazidime—Pancytopenia—Epirubicin—pancreatic cancer	0.00152	0.00152	CcSEcCtD
Ceftazidime—Vomiting—Sunitinib—pancreatic cancer	0.00151	0.00151	CcSEcCtD
Ceftazidime—Body temperature increased—Gemcitabine—pancreatic cancer	0.0015	0.0015	CcSEcCtD
Ceftazidime—Neutropenia—Epirubicin—pancreatic cancer	0.0015	0.0015	CcSEcCtD
Ceftazidime—Rash—Sunitinib—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Ceftazidime—Dermatitis—Sunitinib—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Ceftazidime—Urticaria—Fluorouracil—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Ceftazidime—Headache—Sunitinib—pancreatic cancer	0.00148	0.00148	CcSEcCtD
Ceftazidime—Leukopenia—Docetaxel—pancreatic cancer	0.00148	0.00148	CcSEcCtD
Ceftazidime—Body temperature increased—Fluorouracil—pancreatic cancer	0.00148	0.00148	CcSEcCtD
Ceftazidime—Eosinophilia—Doxorubicin—pancreatic cancer	0.00147	0.00147	CcSEcCtD
Ceftazidime—Hypersensitivity—Irinotecan—pancreatic cancer	0.00144	0.00144	CcSEcCtD
Ceftazidime—Convulsion—Docetaxel—pancreatic cancer	0.00143	0.00143	CcSEcCtD
Ceftazidime—Infestation NOS—Epirubicin—pancreatic cancer	0.00143	0.00143	CcSEcCtD
Ceftazidime—Infestation—Epirubicin—pancreatic cancer	0.00143	0.00143	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.00141	0.00141	CcSEcCtD
Ceftazidime—Nausea—Sunitinib—pancreatic cancer	0.00141	0.00141	CcSEcCtD
Ceftazidime—Pancytopenia—Doxorubicin—pancreatic cancer	0.00141	0.00141	CcSEcCtD
Ceftazidime—Renal failure—Epirubicin—pancreatic cancer	0.0014	0.0014	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.0014	0.0014	CcSEcCtD
Ceftazidime—Jaundice—Epirubicin—pancreatic cancer	0.00139	0.00139	CcSEcCtD
Ceftazidime—Neutropenia—Doxorubicin—pancreatic cancer	0.00138	0.00138	CcSEcCtD
Ceftazidime—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00138	0.00138	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.00135	0.00135	CcSEcCtD
Ceftazidime—Anaphylactic shock—Docetaxel—pancreatic cancer	0.00135	0.00135	CcSEcCtD
Ceftazidime—Pruritus—Gemcitabine—pancreatic cancer	0.00135	0.00135	CcSEcCtD
Ceftazidime—Diarrhoea—Irinotecan—pancreatic cancer	0.00134	0.00134	CcSEcCtD
Ceftazidime—Agranulocytosis—Epirubicin—pancreatic cancer	0.00133	0.00133	CcSEcCtD
Ceftazidime—Nervous system disorder—Docetaxel—pancreatic cancer	0.00132	0.00132	CcSEcCtD
Ceftazidime—Pruritus—Fluorouracil—pancreatic cancer	0.00132	0.00132	CcSEcCtD
Ceftazidime—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00132	0.00132	CcSEcCtD
Ceftazidime—Infestation NOS—Doxorubicin—pancreatic cancer	0.00132	0.00132	CcSEcCtD
Ceftazidime—Infestation—Doxorubicin—pancreatic cancer	0.00132	0.00132	CcSEcCtD
Ceftazidime—Skin disorder—Docetaxel—pancreatic cancer	0.00131	0.00131	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.00131	0.00131	CcSEcCtD
Ceftazidime—Diarrhoea—Gemcitabine—pancreatic cancer	0.0013	0.0013	CcSEcCtD
Ceftazidime—Renal failure—Doxorubicin—pancreatic cancer	0.0013	0.0013	CcSEcCtD
Ceftazidime—Dizziness—Irinotecan—pancreatic cancer	0.00129	0.00129	CcSEcCtD
Ceftazidime—Haemoglobin—Epirubicin—pancreatic cancer	0.00129	0.00129	CcSEcCtD
Ceftazidime—Jaundice—Doxorubicin—pancreatic cancer	0.00129	0.00129	CcSEcCtD
Ceftazidime—Haemorrhage—Epirubicin—pancreatic cancer	0.00128	0.00128	CcSEcCtD
Ceftazidime—Diarrhoea—Fluorouracil—pancreatic cancer	0.00128	0.00128	CcSEcCtD
Ceftazidime—Hypotension—Docetaxel—pancreatic cancer	0.00126	0.00126	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.00125	0.00125	CcSEcCtD
Ceftazidime—Vomiting—Irinotecan—pancreatic cancer	0.00124	0.00124	CcSEcCtD
Ceftazidime—Dizziness—Fluorouracil—pancreatic cancer	0.00124	0.00124	CcSEcCtD
Ceftazidime—Agranulocytosis—Doxorubicin—pancreatic cancer	0.00123	0.00123	CcSEcCtD
Ceftazidime—Rash—Irinotecan—pancreatic cancer	0.00123	0.00123	CcSEcCtD
Ceftazidime—Dermatitis—Irinotecan—pancreatic cancer	0.00123	0.00123	CcSEcCtD
Ceftazidime—Headache—Irinotecan—pancreatic cancer	0.00122	0.00122	CcSEcCtD
Ceftazidime—Paraesthesia—Docetaxel—pancreatic cancer	0.00121	0.00121	CcSEcCtD
Ceftazidime—Erythema multiforme—Epirubicin—pancreatic cancer	0.00121	0.00121	CcSEcCtD
Ceftazidime—Vomiting—Gemcitabine—pancreatic cancer	0.00121	0.00121	CcSEcCtD
Ceftazidime—Rash—Gemcitabine—pancreatic cancer	0.0012	0.0012	CcSEcCtD
Ceftazidime—Dermatitis—Gemcitabine—pancreatic cancer	0.0012	0.0012	CcSEcCtD
Ceftazidime—Haemoglobin—Doxorubicin—pancreatic cancer	0.00119	0.00119	CcSEcCtD
Ceftazidime—Headache—Gemcitabine—pancreatic cancer	0.00119	0.00119	CcSEcCtD
Ceftazidime—Flushing—Epirubicin—pancreatic cancer	0.00119	0.00119	CcSEcCtD
Ceftazidime—Vomiting—Fluorouracil—pancreatic cancer	0.00119	0.00119	CcSEcCtD
Ceftazidime—Haemorrhage—Doxorubicin—pancreatic cancer	0.00119	0.00119	CcSEcCtD
Ceftazidime—Rash—Fluorouracil—pancreatic cancer	0.00118	0.00118	CcSEcCtD
Ceftazidime—Dermatitis—Fluorouracil—pancreatic cancer	0.00118	0.00118	CcSEcCtD
Ceftazidime—Headache—Fluorouracil—pancreatic cancer	0.00117	0.00117	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00116	0.00116	CcSEcCtD
Ceftazidime—Angiopathy—Epirubicin—pancreatic cancer	0.00116	0.00116	CcSEcCtD
Ceftazidime—Nausea—Irinotecan—pancreatic cancer	0.00116	0.00116	CcSEcCtD
Ceftazidime—Immune system disorder—Epirubicin—pancreatic cancer	0.00116	0.00116	CcSEcCtD
Ceftazidime—Pain—Docetaxel—pancreatic cancer	0.00115	0.00115	CcSEcCtD
Ceftazidime—Nausea—Gemcitabine—pancreatic cancer	0.00113	0.00113	CcSEcCtD
Ceftazidime—Erythema multiforme—Doxorubicin—pancreatic cancer	0.00112	0.00112	CcSEcCtD
Ceftazidime—Nausea—Fluorouracil—pancreatic cancer	0.00111	0.00111	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.0011	0.0011	CcSEcCtD
Ceftazidime—Flushing—Doxorubicin—pancreatic cancer	0.0011	0.0011	CcSEcCtD
Ceftazidime—Dysgeusia—Epirubicin—pancreatic cancer	0.00109	0.00109	CcSEcCtD
Ceftazidime—Angiopathy—Doxorubicin—pancreatic cancer	0.00108	0.00108	CcSEcCtD
Ceftazidime—Immune system disorder—Doxorubicin—pancreatic cancer	0.00107	0.00107	CcSEcCtD
Ceftazidime—Body temperature increased—Docetaxel—pancreatic cancer	0.00107	0.00107	CcSEcCtD
Ceftazidime—Abdominal pain—Docetaxel—pancreatic cancer	0.00107	0.00107	CcSEcCtD
Ceftazidime—Vision blurred—Epirubicin—pancreatic cancer	0.00105	0.00105	CcSEcCtD
Ceftazidime—Agitation—Epirubicin—pancreatic cancer	0.00102	0.00102	CcSEcCtD
Ceftazidime—Dysgeusia—Doxorubicin—pancreatic cancer	0.00101	0.00101	CcSEcCtD
Ceftazidime—Leukopenia—Epirubicin—pancreatic cancer	0.000998	0.000998	CcSEcCtD
Ceftazidime—Hypersensitivity—Docetaxel—pancreatic cancer	0.000994	0.000994	CcSEcCtD
Ceftazidime—Vision blurred—Doxorubicin—pancreatic cancer	0.000972	0.000972	CcSEcCtD
Ceftazidime—Convulsion—Epirubicin—pancreatic cancer	0.000966	0.000966	CcSEcCtD
Ceftazidime—Pruritus—Docetaxel—pancreatic cancer	0.000955	0.000955	CcSEcCtD
Ceftazidime—Agitation—Doxorubicin—pancreatic cancer	0.000948	0.000948	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000943	0.000943	CcSEcCtD
Ceftazidime—Leukopenia—Doxorubicin—pancreatic cancer	0.000924	0.000924	CcSEcCtD
Ceftazidime—Diarrhoea—Docetaxel—pancreatic cancer	0.000923	0.000923	CcSEcCtD
Ceftazidime—Anaphylactic shock—Epirubicin—pancreatic cancer	0.00091	0.00091	CcSEcCtD
Ceftazidime—Convulsion—Doxorubicin—pancreatic cancer	0.000894	0.000894	CcSEcCtD
Ceftazidime—Nervous system disorder—Epirubicin—pancreatic cancer	0.000893	0.000893	CcSEcCtD
Ceftazidime—Dizziness—Docetaxel—pancreatic cancer	0.000892	0.000892	CcSEcCtD
Ceftazidime—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000891	0.000891	CcSEcCtD
Ceftazidime—Skin disorder—Epirubicin—pancreatic cancer	0.000884	0.000884	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000872	0.000872	CcSEcCtD
Ceftazidime—Vomiting—Docetaxel—pancreatic cancer	0.000858	0.000858	CcSEcCtD
Ceftazidime—Rash—Docetaxel—pancreatic cancer	0.000851	0.000851	CcSEcCtD
Ceftazidime—Hypotension—Epirubicin—pancreatic cancer	0.00085	0.00085	CcSEcCtD
Ceftazidime—Dermatitis—Docetaxel—pancreatic cancer	0.00085	0.00085	CcSEcCtD
Ceftazidime—Headache—Docetaxel—pancreatic cancer	0.000845	0.000845	CcSEcCtD
Ceftazidime—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000842	0.000842	CcSEcCtD
Ceftazidime—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000826	0.000826	CcSEcCtD
Ceftazidime—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000825	0.000825	CcSEcCtD
Ceftazidime—Skin disorder—Doxorubicin—pancreatic cancer	0.000818	0.000818	CcSEcCtD
Ceftazidime—Paraesthesia—Epirubicin—pancreatic cancer	0.000817	0.000817	CcSEcCtD
Ceftazidime—Nausea—Docetaxel—pancreatic cancer	0.000802	0.000802	CcSEcCtD
Ceftazidime—Hypotension—Doxorubicin—pancreatic cancer	0.000787	0.000787	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000786	0.000786	CcSEcCtD
Ceftazidime—Pain—Epirubicin—pancreatic cancer	0.000778	0.000778	CcSEcCtD
Ceftazidime—Paraesthesia—Doxorubicin—pancreatic cancer	0.000756	0.000756	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000744	0.000744	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000727	0.000727	CcSEcCtD
Ceftazidime—Urticaria—Epirubicin—pancreatic cancer	0.000723	0.000723	CcSEcCtD
Ceftazidime—Pain—Doxorubicin—pancreatic cancer	0.00072	0.00072	CcSEcCtD
Ceftazidime—Abdominal pain—Epirubicin—pancreatic cancer	0.00072	0.00072	CcSEcCtD
Ceftazidime—Body temperature increased—Epirubicin—pancreatic cancer	0.00072	0.00072	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000689	0.000689	CcSEcCtD
Ceftazidime—Hypersensitivity—Epirubicin—pancreatic cancer	0.000671	0.000671	CcSEcCtD
Ceftazidime—Urticaria—Doxorubicin—pancreatic cancer	0.000669	0.000669	CcSEcCtD
Ceftazidime—Body temperature increased—Doxorubicin—pancreatic cancer	0.000666	0.000666	CcSEcCtD
Ceftazidime—Abdominal pain—Doxorubicin—pancreatic cancer	0.000666	0.000666	CcSEcCtD
Ceftazidime—Pruritus—Epirubicin—pancreatic cancer	0.000644	0.000644	CcSEcCtD
Ceftazidime—Diarrhoea—Epirubicin—pancreatic cancer	0.000623	0.000623	CcSEcCtD
Ceftazidime—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00062	0.00062	CcSEcCtD
Ceftazidime—Dizziness—Epirubicin—pancreatic cancer	0.000602	0.000602	CcSEcCtD
Ceftazidime—Pruritus—Doxorubicin—pancreatic cancer	0.000596	0.000596	CcSEcCtD
Ceftazidime—Vomiting—Epirubicin—pancreatic cancer	0.000579	0.000579	CcSEcCtD
Ceftazidime—Diarrhoea—Doxorubicin—pancreatic cancer	0.000576	0.000576	CcSEcCtD
Ceftazidime—Rash—Epirubicin—pancreatic cancer	0.000574	0.000574	CcSEcCtD
Ceftazidime—Dermatitis—Epirubicin—pancreatic cancer	0.000573	0.000573	CcSEcCtD
Ceftazidime—Headache—Epirubicin—pancreatic cancer	0.00057	0.00057	CcSEcCtD
Ceftazidime—Dizziness—Doxorubicin—pancreatic cancer	0.000557	0.000557	CcSEcCtD
Ceftazidime—Nausea—Epirubicin—pancreatic cancer	0.000541	0.000541	CcSEcCtD
Ceftazidime—Vomiting—Doxorubicin—pancreatic cancer	0.000535	0.000535	CcSEcCtD
Ceftazidime—Rash—Doxorubicin—pancreatic cancer	0.000531	0.000531	CcSEcCtD
Ceftazidime—Dermatitis—Doxorubicin—pancreatic cancer	0.000531	0.000531	CcSEcCtD
Ceftazidime—Headache—Doxorubicin—pancreatic cancer	0.000528	0.000528	CcSEcCtD
Ceftazidime—Nausea—Doxorubicin—pancreatic cancer	0.0005	0.0005	CcSEcCtD
